CO5680459A2 - Combinacion de un inhibidor de receptor de vegf con un agente quinioterapeutico - Google Patents
Combinacion de un inhibidor de receptor de vegf con un agente quinioterapeuticoInfo
- Publication number
- CO5680459A2 CO5680459A2 CO06031465A CO06031465A CO5680459A2 CO 5680459 A2 CO5680459 A2 CO 5680459A2 CO 06031465 A CO06031465 A CO 06031465A CO 06031465 A CO06031465 A CO 06031465A CO 5680459 A2 CO5680459 A2 CO 5680459A2
- Authority
- CO
- Colombia
- Prior art keywords
- inhibitor
- compound
- inhibitors
- agent
- protein
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 102000014150 Interferons Human genes 0.000 abstract 2
- 108010050904 Interferons Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 229940097396 Aminopeptidase inhibitor Drugs 0.000 abstract 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 abstract 1
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- 102400000967 Bradykinin Human genes 0.000 abstract 1
- 101800004538 Bradykinin Proteins 0.000 abstract 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 abstract 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 abstract 1
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 abstract 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 abstract 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 229920002971 Heparan sulfate Polymers 0.000 abstract 1
- 229940122588 Heparanase inhibitor Drugs 0.000 abstract 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 abstract 1
- 101710181812 Methionine aminopeptidase Proteins 0.000 abstract 1
- 102000029749 Microtubule Human genes 0.000 abstract 1
- 108091022875 Microtubule Proteins 0.000 abstract 1
- GPVKLYONJSSZFL-UHFFFAOYSA-N NSC 750259 Natural products CCC(C)C=CC(O)C(O)C(O)C(OC)C(=O)NC1CCCCNC1=O GPVKLYONJSSZFL-UHFFFAOYSA-N 0.000 abstract 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 abstract 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 229940121856 Somatostatin receptor antagonist Drugs 0.000 abstract 1
- 229940123582 Telomerase inhibitor Drugs 0.000 abstract 1
- 108091033399 Telomestatin Proteins 0.000 abstract 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 abstract 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000002280 anti-androgenic effect Effects 0.000 abstract 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 230000009949 anti-apoptotic pathway Effects 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 239000000051 antiandrogen Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
- 229930195545 bengamide Natural products 0.000 abstract 1
- 230000008512 biological response Effects 0.000 abstract 1
- 150000004663 bisphosphonates Chemical class 0.000 abstract 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 1
- 229960001442 gonadorelin Drugs 0.000 abstract 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 abstract 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 229940047124 interferons Drugs 0.000 abstract 1
- 230000005865 ionizing radiation Effects 0.000 abstract 1
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 abstract 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 abstract 1
- 210000004688 microtubule Anatomy 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
- 231100000590 oncogenic Toxicity 0.000 abstract 1
- 230000002246 oncogenic effect Effects 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003058 platinum compounds Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 239000003277 telomerase inhibitor Substances 0.000 abstract 1
- YVSQVYZBDXIXCC-INIZCTEOSA-N telomestatin Chemical compound N=1C2=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(=C(O1)C)N=C1C(=C(O1)C)N=C1[C@@]1([H])N=C2SC1 YVSQVYZBDXIXCC-INIZCTEOSA-N 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 230000034512 ubiquitination Effects 0.000 abstract 1
- 238000010798 ubiquitination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- Un método para la prevención o el tratamiento deenfermedades proliferativas, el cual comprende administrarcantidades farmacéuticamente efectivas de una combinación de: (a) un compuesto inhibidor del factor de crecimientoendotelial vascular; y uno o más agentes quimioterapéuticos seleccionados a partir del grupo que consiste en: i. un inhibidor de aromatasa; ii. un anti-estrógeno, un anti-andrógeno (en especial enel caso de cáncer de próstata), o un agonista de gonadorelina; iii. un inhibidor de topoisomerasa I ó un inhibidor detopoisomerasa II; iv. un agente activo en microtúbulos, un agentealquilante, un anti-metabolito anti-neoplástico, o un compuesto de platina; v. un compuesto que dirige/reduce una actividad dequinasa de proteína o de lípido o una actividad de fosfatasa de proteína o lípido, un compuesto anti-angiogénico adicional, o un compuesto que induzca procesos de diferenciación celular; vi. un receptor de bradiquinina 1 ó un antagonista de angiotensina II; vii. un inhibidor de ciclo-oxigenasa, un bisfosfonato, un inhibidor de heparanasa (que previene la degradación del sulfato de heparano), por ejemplo PI-88, un modificador de la respuesta biológica, de preferencia una linfocina o interferones, por ejemplo interferón y, un inhibidor de ubiquitinación, o un inhibidor que bloquee las sendas anti-apoptóticas; viii. un inhibidor de las isoformas oncogénicas Ras ó un inhibidor de farnesil-transferasa; ix. un inhibidor de telomerasa, por ejemplo telomestatina; x. un inhibidor de proteasa, un inhibidor de metaloproteinasa de matriz, un inhibidor de aminopeptidasa de metionina, por ejemplo bengamida o un derivado de la misma, o un inhibidor de proteasoma, por ejemplo PS-341; xi. agentes utilizados en el tratamiento de malignidades hematológicas o inhibidores de quinasa de tirosina tipo FMS; xii. inhibidores de HSP90; xiii. inhibidores HDAC; xiv. inhibidores de mTOR; xv. antagonistas del receptor de somatostatina; xvi. antagonistas de integrina; xvii. compuestos anti-Ieucémicos; xviii. planteamientos que dañan las células tumorales tales como radiación ionizante; ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50525003P | 2003-09-23 | 2003-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5680459A2 true CO5680459A2 (es) | 2006-09-29 |
Family
ID=34375569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO06031465A CO5680459A2 (es) | 2003-09-23 | 2006-03-30 | Combinacion de un inhibidor de receptor de vegf con un agente quinioterapeutico |
Country Status (16)
Country | Link |
---|---|
US (1) | US20080085902A1 (es) |
EP (1) | EP1682181A2 (es) |
JP (1) | JP2007505938A (es) |
KR (1) | KR20060097000A (es) |
CN (1) | CN1856327A (es) |
AU (1) | AU2004273615B2 (es) |
BR (1) | BRPI0414698A (es) |
CA (1) | CA2537991A1 (es) |
CO (1) | CO5680459A2 (es) |
CR (1) | CR8283A (es) |
EA (1) | EA200600495A1 (es) |
EC (1) | ECSP066437A (es) |
IL (1) | IL174214A0 (es) |
MX (1) | MXPA06003163A (es) |
NO (1) | NO20061777L (es) |
WO (1) | WO2005027972A2 (es) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7399480B2 (en) | 1997-09-26 | 2008-07-15 | Abbott Laboratories | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices |
US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ES2377847T3 (es) | 1999-01-13 | 2012-04-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
IL155447A0 (en) | 2000-10-20 | 2003-11-23 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
NZ562412A (en) * | 2003-02-21 | 2009-02-28 | Resmed Ltd | Nasal assembly for pillow mask |
JPWO2004080462A1 (ja) | 2003-03-10 | 2006-06-08 | エーザイ株式会社 | c−Kitキナーゼ阻害剤 |
WO2004113274A2 (en) | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
EP1683785B1 (en) | 2003-11-11 | 2013-10-16 | Eisai R&D Management Co., Ltd. | Urea derivative and process for producing the same |
WO2005070020A2 (en) | 2004-01-23 | 2005-08-04 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
WO2005115405A1 (en) | 2004-04-28 | 2005-12-08 | Molecules For Health, Inc. | Methods for treating or preventing restenosis and other vascular proliferative disorders |
ES2677562T3 (es) | 2004-05-27 | 2018-08-03 | The Regents Of The University Of Colorado | Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer |
AU2005283422C1 (en) | 2004-09-17 | 2017-02-02 | Eisai R & D Management Co., Ltd. | Medicinal composition |
JP2008514576A (ja) * | 2004-09-27 | 2008-05-08 | アストラゼネカ アクチボラグ | Azd2171およびイマチニブを含む癌組合せ療法 |
ME01498B (me) | 2004-11-18 | 2014-04-20 | Synta Pharmaceuticals Corp | Jedinjenja triazola koja modulišu aktivnost hsp90 |
KR20140016402A (ko) | 2005-02-18 | 2014-02-07 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 조합 및 투여 방식, 및 조합 요법 |
US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
WO2006094626A1 (en) * | 2005-03-07 | 2006-09-14 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
JP2009502960A (ja) * | 2005-07-27 | 2009-01-29 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ |
EP2281901B1 (en) | 2005-08-02 | 2013-11-27 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
KR20080064988A (ko) * | 2005-10-24 | 2008-07-10 | 노파르티스 아게 | 히스톤 데아세틸라제 억제제 및 방사선의 조합 |
CN101316590B (zh) * | 2005-11-07 | 2011-08-03 | 卫材R&D管理有限公司 | 血管生成抑制剂和c-kit激酶抑制剂的组合使用 |
CN100441222C (zh) * | 2005-12-09 | 2008-12-10 | 中国科学院广州生物医药与健康研究院 | 化合物ps-341在制备治疗急性髓性白血病药物中的应用 |
FR2895258B1 (fr) * | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | Combinaison comprenant de la combretastatine et des agents anticancereux |
US20070258976A1 (en) * | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
US20090209580A1 (en) | 2006-05-18 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
EP2086930A2 (en) | 2006-06-12 | 2009-08-12 | Novartis AG | Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide |
JP5368096B2 (ja) | 2006-08-28 | 2013-12-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 未分化型胃癌に対する抗腫瘍剤 |
KR101433629B1 (ko) | 2006-09-11 | 2014-08-27 | 쿠리스 인코퍼레이션 | 아연 결합 부분을 함유한 티로신 키나아제 억제제 |
US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
EP2030615A3 (en) | 2007-08-13 | 2009-12-02 | ELFORD, Howard L. | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases |
WO2009036066A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
EP2060565A1 (en) * | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
JP5647098B2 (ja) | 2008-03-21 | 2014-12-24 | ザ ユニヴァーシティー オヴ シカゴ | オピオイド拮抗薬とmTOR阻害薬を用いた治療 |
JP5425180B2 (ja) | 2008-03-27 | 2014-02-26 | ザイモジェネティクス, インコーポレイテッド | PDGFRβおよびVEGF−Aを阻害するための組成物および方法 |
WO2010091234A2 (en) | 2009-02-06 | 2010-08-12 | The General Hospital Corporation | Methods of treating vascular lesions |
WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
JP5593323B2 (ja) * | 2009-09-30 | 2014-09-24 | 株式会社 資生堂 | ヘパラナーゼ活性阻害剤 |
CA2785970A1 (en) | 2010-01-14 | 2011-07-21 | Nagoya City University | Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability |
PL2552415T3 (pl) | 2010-03-29 | 2017-03-31 | Abraxis Bioscience, Llc | Sposoby leczenia nowotworu |
JP6242213B2 (ja) | 2010-03-29 | 2017-12-06 | アブラクシス バイオサイエンス, エルエルシー | 薬物送達および治療用薬剤の有効性を向上させる方法 |
US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
MY162903A (en) | 2010-06-04 | 2017-07-31 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
ES2573515T3 (es) | 2010-06-25 | 2016-06-08 | Eisai R&D Management Co., Ltd. | Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados |
JPWO2012105610A1 (ja) | 2011-02-02 | 2014-07-03 | 株式会社三和化学研究所 | 眼内血管新生及び/又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 |
CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
AU2012332421A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of Hsp90 inhibitors with topoisomerase I inhibitors |
CA2853806C (en) | 2011-11-02 | 2020-07-14 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
BR112014011223A8 (pt) | 2011-11-11 | 2023-01-31 | Novartis Ag | Método de tratar uma doença proliferativa |
WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
RU2015121367A (ru) * | 2012-11-08 | 2017-01-10 | Новартис Аг | Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний |
KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
EP3169686A4 (en) * | 2014-07-14 | 2018-01-24 | Signal Pharmaceuticals, LLC | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
KR102512940B1 (ko) | 2014-08-28 | 2023-03-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
BR102014023144B1 (pt) * | 2014-09-18 | 2020-12-15 | Universidade De São Paulo - Usp | peptídeos sintéticos ligantes de receptores de vegf e seus usos |
JP6792546B2 (ja) | 2015-02-25 | 2020-11-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体の苦味抑制方法 |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
US20220229072A1 (en) | 2019-06-04 | 2022-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
KR102371269B1 (ko) * | 2020-03-11 | 2022-03-07 | 연세대학교 산학협력단 | VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
WO2002066479A1 (fr) * | 2001-02-23 | 2002-08-29 | Banyu Pharmaceutical Co.,Ltd. | Derives de l'isoindole |
NZ531484A (en) * | 2001-09-12 | 2007-02-23 | Novartis Ag | Use of 4-pyridylmethylphthalazines for cancer treatment |
PT1441714E (pt) * | 2001-10-25 | 2008-03-10 | Novartis Ag | Combinações compreendendo um inibidor selectivo da ciclo-oxigenase 2 |
EP1453513A1 (en) * | 2001-12-03 | 2004-09-08 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
-
2004
- 2004-09-23 US US10/573,163 patent/US20080085902A1/en not_active Abandoned
- 2004-09-23 MX MXPA06003163A patent/MXPA06003163A/es not_active Application Discontinuation
- 2004-09-23 WO PCT/EP2004/010686 patent/WO2005027972A2/en active Application Filing
- 2004-09-23 JP JP2006527348A patent/JP2007505938A/ja active Pending
- 2004-09-23 BR BRPI0414698-0A patent/BRPI0414698A/pt not_active IP Right Cessation
- 2004-09-23 CN CNA2004800275441A patent/CN1856327A/zh active Pending
- 2004-09-23 AU AU2004273615A patent/AU2004273615B2/en not_active Ceased
- 2004-09-23 CA CA002537991A patent/CA2537991A1/en not_active Abandoned
- 2004-09-23 KR KR1020067005644A patent/KR20060097000A/ko not_active Application Discontinuation
- 2004-09-23 EA EA200600495A patent/EA200600495A1/ru unknown
- 2004-09-23 EP EP04765542A patent/EP1682181A2/en not_active Withdrawn
-
2006
- 2006-03-09 IL IL174214A patent/IL174214A0/en unknown
- 2006-03-14 CR CR8283A patent/CR8283A/es not_active Application Discontinuation
- 2006-03-17 EC EC2006006437A patent/ECSP066437A/es unknown
- 2006-03-30 CO CO06031465A patent/CO5680459A2/es not_active Application Discontinuation
- 2006-04-21 NO NO20061777A patent/NO20061777L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA06003163A (es) | 2006-06-05 |
IL174214A0 (en) | 2006-08-01 |
WO2005027972A3 (en) | 2005-11-03 |
CN1856327A (zh) | 2006-11-01 |
EP1682181A2 (en) | 2006-07-26 |
WO2005027972A2 (en) | 2005-03-31 |
KR20060097000A (ko) | 2006-09-13 |
ECSP066437A (es) | 2006-09-18 |
BRPI0414698A (pt) | 2006-11-28 |
JP2007505938A (ja) | 2007-03-15 |
AU2004273615B2 (en) | 2009-01-15 |
AU2004273615A1 (en) | 2005-03-31 |
EA200600495A1 (ru) | 2006-10-27 |
CR8283A (es) | 2006-10-10 |
CA2537991A1 (en) | 2005-03-31 |
US20080085902A1 (en) | 2008-04-10 |
NO20061777L (no) | 2006-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5680459A2 (es) | Combinacion de un inhibidor de receptor de vegf con un agente quinioterapeutico | |
JP2004525899A5 (es) | ||
Yabluchanskiy et al. | Matrix metalloproteinases: drug targets for myocardial infarction | |
ATE407679T1 (de) | Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten | |
JP2007505938A5 (es) | ||
EP1539234A4 (en) | METHODS OF PREVENTING OR TREATING CELLULAR MALIGNITES BY ADMINISTERING CD2 ANTAGONISTS | |
UY28438A1 (es) | Composicion de un antagonista de vegf y de un agente antiproliferativo | |
AR065335A1 (es) | Combinaciones de agentes terapeuticos para el tratamiento de cancer | |
DE602004020638D1 (de) | Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten | |
RU2007141994A (ru) | Применение антител к cd25 в иммунотерапии | |
TW200628151A (en) | Combinations of therapeutic agents for treating cancer | |
MXPA05005296A (es) | Bis-aril sulfonamidas. | |
RU2003127391A (ru) | Лечение рака | |
BG108214A (en) | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist | |
TW200700082A (en) | Therapy of prostate cancer with ctla4 antibodies and hormonal therapy | |
MXPA05012762A (es) | Derivados de la quinazolina macrociclica como agentes antiproliferativos. | |
WO2004050033A3 (en) | Method of treating cancers | |
CL2011001445A1 (es) | Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias | |
TW200505443A (en) | Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | |
AR034071A1 (es) | Combinaciones antineoplasicas | |
ATE557007T1 (de) | Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen | |
TR200100314T2 (tr) | Migren tekrarının önlenmesi | |
WO2007024752A3 (en) | Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders | |
DE60331821D1 (de) | Sondenstabilisierte bogenentladungslampe | |
UY25855A1 (es) | 4,5-azolo-oxindoles útiles en el tratamiento o control de los desórdenes proliferativos celulares |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |